Logo

Sneak a Peek at Pfizer's Compounds

May 20, 2009

Pfizer is letting people screen its proprietary compounds, says Derek Lowe at In the Pipeline. "As I understand it, you need to come to them with a reasonably formatted HTS assay, and there's a fee in the high hundreds of thousands to run the screen," Lowe writes, and that set-up doesn't strike him as "much of a moneymaker." Instead, he says it's probably a way for Pfizer to make deals with smaller companies since the compounds are likely covered by Pfizer patents.

Breaking News
The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.